|
Jun 25
|
Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections
|
|
Jun 24
|
Those who invested in Recce Pharmaceuticals (ASX:RCE) five years ago are up 170%
|
|
Mar 14
|
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
|
|
Mar 13
|
Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting
|
|
Mar 12
|
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance
|
|
Feb 27
|
Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections
|
|
Jan 15
|
Those who invested in Recce Pharmaceuticals (ASX:RCE) five years ago are up 247%
|
|
Dec 19
|
Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program
|
|
Dec 18
|
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea
|
|
Nov 27
|
Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives
|
|
Jul 13
|
Recce Pharmaceuticals Receives A$801,604 Research and Development (R&D) Rebate Advance
|